As U.S. markets navigate a mix of earnings reports and geopolitical developments, investors are keenly watching how these factors influence major indices like the Dow Jones, S&P 500, and Nasdaq Composite. For those interested in exploring investment opportunities beyond the usual blue-chip stocks, penny stocks present a unique avenue worth considering. Despite their somewhat outdated moniker, penny stocks can offer significant growth potential when backed by solid financial fundamentals.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.766 | $6.09M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $143.12M | ★★★★★★ |
| PHX Minerals (NYSE:PHX) | $3.56 | $139.05M | ★★★★★☆ |
| So-Young International (NasdaqGM:SY) | $1.25 | $90.58M | ★★★★☆☆ |
| ZTEST Electronics (OTCPK:ZTST.F) | $0.23 | $8.33M | ★★★★★★ |
| Greenland Technologies Holding (NasdaqCM:GTEC) | $2.43 | $29.91M | ★★★★★★ |
| Better Choice (NYSEAM:BTTR) | $1.75 | $3.19M | ★★★★★★ |
| RLX Technology (NYSE:RLX) | $1.82 | $2.15B | ★★★★★★ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.8363 | $84.72M | ★★★★★☆ |
Click here to see the full list of 748 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Achilles Therapeutics
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Achilles Therapeutics plc is a biopharmaceutical company focused on developing precision T cell therapies for the treatment of solid tumors, with a market cap of $43.14 million.
Operations: Achilles Therapeutics plc does not currently report any revenue segments.
Market Cap: $43.14M
Achilles Therapeutics, with a market cap of US$43.14 million, is pre-revenue and currently unprofitable. The company has no debt and maintains sufficient short-term assets to cover liabilities, offering some financial stability despite its negative return on equity of -64.84%. Recent strategic shifts include discontinuing certain clinical trials and exploring new partnerships in cancer treatment modalities like neoantigen vaccines. Achilles is actively seeking value-maximizing strategies with the help of BofA Securities, considering options such as acquisitions or mergers. However, its share price remains highly volatile, reflecting inherent risks associated with penny stocks in biotech sectors.
- Get an in-depth perspective on Achilles Therapeutics’ performance by reading our balance sheet health report here.
- Examine Achilles Therapeutics’ earnings growth report to understand how analysts expect it to perform.
Greenpro Capital
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Greenpro Capital Corp. offers financial consulting and corporate advisory services to small and medium-sized businesses mainly in Hong Kong, Malaysia, and China, with a market capitalization of $7.27 million.
Operations: No specific revenue segments have been reported.
Market Cap: $7.27M
Greenpro Capital Corp., with a market cap of US$7.27 million, is pre-revenue and currently unprofitable, facing challenges such as a negative return on equity of -137.34%. The company recently reported declining revenues and increased net losses for the third quarter of 2024. Despite being debt-free and having short-term assets exceeding liabilities, Greenpro Capital has less than a year of cash runway. Its stock faces potential delisting from Nasdaq due to prolonged low bid prices, prompting consideration of corrective actions like reverse stock splits to meet compliance requirements amidst high share price volatility.
- Click here and access our complete financial health analysis report to understand the dynamics of Greenpro Capital.
- Gain insights into Greenpro Capital’s historical outcomes by reviewing our past performance report.
Texas Mineral Resources
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Texas Mineral Resources Corp. is engaged in the acquisition, exploration, and development of mineral properties in the United States with a market cap of $19.63 million.
Operations: Currently, there are no reported revenue segments for the company.
Market Cap: $19.63M
Texas Mineral Resources Corp., with a market cap of US$19.63 million, is pre-revenue and currently unprofitable, showing increased losses over the past five years at 7% per year. The company has less than a year of cash runway and no reported revenue segments, indicating potential financial constraints. Despite being debt-free and having short-term assets exceeding liabilities by US$593.6K, its share price has been highly volatile recently. The board is experienced with an average tenure of 10.8 years, but the management team’s experience level is unclear due to insufficient data on their tenure.
- Navigate through the intricacies of Texas Mineral Resources with our comprehensive balance sheet health report here.
- Evaluate Texas Mineral Resources’ historical performance by accessing our past performance report.
Taking Advantage
- Unlock our comprehensive list of 748 US Penny Stocks by clicking here.
- Shareholder in one or more of these companies? Ensure you’re never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it’s free and covers every market in the world.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven’t yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:ACHL NasdaqCM:GRNQ and OTCPK:TMRC.